Clinical lung cancerHumansCarcinomaNon-Small-Cell LungFemaleMale
Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.
James Ch Yang, Myung-Ju Ahn, Joo-Hang Kim, Yun-Gyoo Lee, Ji-Youn Han, Ki Hyeong Lee, Anastasia Zimina, Dong-Wan Kim, Kyung-Hee Lee, Sung Sook Lee, Chun Sen Lim, Yueh Ni Lim, Young Joo Min, Sergey Orlov, Youngjoo Lee
Published: 202510.1016/j.cllc.2025.08.007
Abstract
BACKGROUND: Lazertinib, a brain-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), significantly improved efficacy in patients with treatment-naïve, EGFR-mutated advanced non-small cell lung cancer (N…
Preview only. Read the full abstract at the source